ace-011 and Hemoglobinopathies

ace-011 has been researched along with Hemoglobinopathies* in 1 studies

Reviews

1 review(s) available for ace-011 and Hemoglobinopathies

Article	Year
Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production. Hematology/oncology clinics of North America, 2014, Volume: 28, Issue:2 Use of new compound such as inhibitors of JAK2 or transforming growth factor β-like molecules might soon revolutionize the treatment of β-thalassemia and related disorders. However, this situation requires careful optimization, noting the potential for off-target immune suppression for JAK2 inhibitors and the lack of mechanistic insights for the use of the ligand trap soluble molecules that sequester ligands of activin receptor IIA and B. Topics: Activin Receptors, Type II; beta-Thalassemia; Erythrocytes; Erythropoiesis; Hemoglobinopathies; Humans; Janus Kinase 2; Molecular Targeted Therapy; Recombinant Fusion Proteins	2014

Article

Year

Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.

Hematology/oncology clinics of North America, 2014, Volume: 28, Issue:2

Use of new compound such as inhibitors of JAK2 or transforming growth factor β-like molecules might soon revolutionize the treatment of β-thalassemia and related disorders. However, this situation requires careful optimization, noting the potential for off-target immune suppression for JAK2 inhibitors and the lack of mechanistic insights for the use of the ligand trap soluble molecules that sequester ligands of activin receptor IIA and B.

Topics: Activin Receptors, Type II; beta-Thalassemia; Erythrocytes; Erythropoiesis; Hemoglobinopathies; Humans; Janus Kinase 2; Molecular Targeted Therapy; Recombinant Fusion Proteins

2014